We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01159613
Recruitment Status : Completed
First Posted : July 9, 2010
Last Update Posted : July 9, 2010
Hillel Yafe MC Hadera
Information provided by:
Ziv Hospital

Brief Summary:
The working hypothesis is that the low HDL serum level predict favorable response to anti viral treatment in chronic HCV (genotype 1) viral infection. This might be used to improve the rate of sustained virologic response.

Condition or disease Intervention/treatment
Chronic Hepatitis C Viral Infection Other: Responders Other: Non Responders

Detailed Description:

Lipoproteins are closely connected to the process of hepatitis C virus (HCV) infection. Metabolic syndrome predicts negative treatment outcome in HCV infection.

Aim: to assess the association between lipids components of the metabolic syndrome and sustained viral response (SVR).

Study Type : Observational
Actual Enrollment : 80 participants
Time Perspective: Prospective
Official Title: Do Low HDL Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?
Study Start Date : April 2008
Primary Completion Date : October 2008
Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Non Responders
Non Responders
Other: Non Responders
Non Responders
RESPONDERS Other: Responders

Primary Outcome Measures :
  1. sustained viral response [ Time Frame: 72 weeks ]
    achieving SVR

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
chronic HCV genotype 1 naïve patients

Inclusion Criteria:

  • Chronic HCV genotype 1 naive patients

Exclusion Criteria:

  • Co infection with HBV, HIV, HDV
  • Decompensated liver disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01159613

Ziv medical center liver unit
Safed, Israel, Israel
Sponsors and Collaborators
Ziv Hospital
Hillel Yafe MC Hadera

Responsible Party: Liver Clinic, Ziv medical center
ClinicalTrials.gov Identifier: NCT01159613     History of Changes
Other Study ID Numbers: HDL + HCV
First Posted: July 9, 2010    Key Record Dates
Last Update Posted: July 9, 2010
Last Verified: July 2010

Keywords provided by Ziv Hospital:
Cholesterol level
fibrosis score

Additional relevant MeSH terms:
Communicable Diseases
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Virus Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections